Cincinnati Eye Institute
Cincinnati Eye Institute
Cincinnati, Ohio, United States22 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-30 | NCT06635148 | |
| ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study | Eye Diseases, Hereditary, Geographic Atrophy, Skin Abnormalities, Skin and Connective Tissue Diseases, connective tissue disorder, eye disorder, macular degeneration, primary anetoderma, retinal degeneration, retinal disorder, skin disorder | Enrolling by invitation | Phase 2 | 2026-09-28 | NCT05481827 | |
| Extension Study for the Port Delivery System With Ranibizumab (Portal) | Neovascular Age-Related Macular Degeneration | Recruiting | Phase 3 | 2026-09-28 | NCT03683251 | |
| Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants | Macular Telangiectasia Type 2 (MacTel) | Recruiting | Phase 4 | 2026-09-25 | NCT06971939 | |
| Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, autosomal recessive bestrophinopathy, eye disorder, hereditary disease, macular degeneration, retinal degeneration, retinal disorder, vitelliform macular dystrophy, vitelliform macular dystrophy 2 | Recruiting | Phase 1 / Phase 2 | 2026-09-24 | NCT07185256 | |
| A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (GLOBALIGHT) | Dry Age-related Macular Degeneration | Recruiting | Not stated | 2026-09-22 | NCT06351605 | |
| Hydrus® Microstent New Enrollment Post-Approval Study | Glaucoma, Primary Open Angle, eye disorder, glaucoma, ocular hypertension, open-angle glaucoma | Recruiting | Not applicable | 2026-09-22 | NCT04553523 | |
| ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty | Corneal Transplant Failure | Recruiting | Phase 2 | 2026-09-21 | NCT06753916 | |
| A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 3 | 2026-09-18 | NCT06541704 | |
| A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) | diabetic macular edema | Active, not recruiting | Phase 3 | 2026-09-18 | NCT06491914 | |
| A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Stargardt disease, eye disorder, hereditary disease, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 1 | 2026-09-16 | NCT07734064 | |
| NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration | Eye Diseases, Hereditary, Metaplasia, Neovascularization, Pathologic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, age-related macular degeneration, choroidal neovascularization, eye disorder, macular degeneration, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, wet macular degeneration | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-10 | NCT05984927 | |
| A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Stargardt disease, eye disorder, hereditary disease, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Not stated | 2026-08-25 | NCT07425574 | |
| Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration | age-related macular degeneration, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-27 | NCT02286089 | |
| A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome | Presumed Ocular Histoplasmosis | Recruiting | Phase 4 | 2026-07-10 | NCT07695298 | |
| A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa | Eye Diseases, Hereditary, eye disorder, retinal degeneration, retinal disorder | Active, not recruiting | Phase 2 | 2026-06-25 | NCT07174726 | |
| Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Recruiting | Phase 3 | 2026-04-16 | NCT07064759 | |
| A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP | Eye Diseases, Hereditary, eye disorder, retinal degeneration, retinal disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-04-07 | NCT04850118 | |
| Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | Neovascular Age-related Macular Degeneration | Active, not recruiting | Phase 3 | 2025-06-17 | NCT06495918 | |
| A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN) | Eye Diseases, Hereditary, eye disorder, retinal degeneration, retinal disorder | Enrolling by invitation | Phase 2 | 2024-10-30 | NCT06275620 | |
| A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE) | Eye Diseases, Hereditary, eye disorder, retinal degeneration, retinal disorder | Active, not recruiting | Phase 2 | 2024-08-12 | NCT06333249 | |
| Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations | Eye Diseases, Hereditary, eye disorder, retinal degeneration, retinal disorder | Active, not recruiting | Phase 1 / Phase 2 | 2024-05-20 | NCT03316560 |